This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Fast-paced Momentum Stock CareCloud (CCLD) Is Still Trading at a Bargain
by Zacks Equity Research
CareCloud (CCLD) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks Industry Outlook Highlights Medical Systems, Clover Health Investments and CareCloud
by Zacks Equity Research
Medical Systems, Clover Health Investments and CareCloud are part of the Zacks Industry Outlook article.
Buy These 3 Medical Info Systems Stocks to Capitalize on GenAI Boom
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Clover Health Investments and CareCloud are expected to gain from the GenAI wave.
Why Fast-paced Mover CareCloud (CCLD) Is a Great Choice for Value Investors
by Zacks Equity Research
CareCloud (CCLD) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
CareCloud, Inc. (CCLD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CareCloud (CCLD) delivered earnings and revenue surprises of 50% and 0.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Lags Q2 Earnings Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -40% and 2.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical, Inc. (OM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Outset Medical (OM) delivered earnings and revenue surprises of -9.30% and 12.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Definitive Healthcare Corp. (DH) Meets Q2 Earnings Estimates
by Zacks Equity Research
Definitive Healthcare (DH) delivered earnings and revenue surprises of 0% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CareCloud, Inc. (CCLD) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Annexon (ANNX) This Year?
by Zacks Equity Research
Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights Byrna Technologies, CareCloud, American Superconductor, Alphabet and NVIDIA
by Zacks Equity Research
Byrna Technologies, CareCloud, American Superconductor, Alphabet and NVIDIA are part of the Zacks top Analyst Blog.
5 Top Tech Stocks to Win Big With Nasdaq on a Roll
by Tirthankar Chakraborty
Invest in Byrna Technologies (BYRN), CareCloud (CCLD), American Superconductor (AMSC), Alphabet (GOOGL) and NVIDIA (NVDA), which are poised to make the most of the Nasdaq's upward movement banking on rate cut hopefulness.
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how CareCloud, Inc. (CCLD) and Context Therapeutics Inc. (CNTX) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights CareCloud, DaVita, RadNet, SkyWest and American Express
by Zacks Equity Research
CareCloud, DaVita, RadNet, SkyWest and American Express are included in this Analyst Blog.
5 Stocks to Gain as Service Side of the Economy Bounces Back
by Tirthankar Chakraborty
With service sector activity rebounding in recent times, it's worth placing bets on stocks such as CareCloud (CCLD), DaVita (DVA), RadNet (RDNT), SkyWest (SKYW) and American Express (AXP).
Are Investors Undervaluing CareCloud (CCLD) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Despite Fast-paced Momentum, CareCloud (CCLD) Is Still a Bargain Stock
by Zacks Equity Research
CareCloud (CCLD) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
CareCloud (CCLD) Upgraded to Buy: Here's Why
by Zacks Equity Research
CareCloud (CCLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CareCloud, Inc. (CCLD) and Heron Therapeutics (HRTX) have performed compared to their sector so far this year.
Should You Buy CareCloud, Inc. (CCLD) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CareCloud, Inc. (CCLD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CareCloud (CCLD) delivered earnings and revenue surprises of 93.75% and 2.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
TruBridge (TBRG) Q1 Earnings Miss Estimates
by Zacks Equity Research
TruBridge (TBRG) delivered earnings and revenue surprises of -13.64% and 1.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical, Inc. (OM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Outset Medical (OM) delivered earnings and revenue surprises of -7.55% and 7.80%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 137.50% and 4.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of 0% and 11.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?